thiazoles has been researched along with sipoglitazar in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asahi, S; Kawaguchi, N; Kiyota, Y; Kondo, T; Nishihara, M; Sudo, M; Takahashi, J | 1 |
| Asahi, S; Kamiguchi, H; Kawaguchi, N; Kiyota, Y; Kondo, T; Maeshiba, Y; Nishihara, M; Sudo, M; Tagawa, Y; Takahashi, J | 1 |
| Kinley, J; Nishihara, M; Scott, G; Stringer, F; Urquhart, R; Valbuena, M | 1 |
| Danhof, M; DeJongh, J; Karim, A; Ploeger, BA; Scott, G; Stringer, F; Urquhart, R | 1 |
| Asahi, S; Hiura, Y; Kawaguchi, N; Nishihara, M; Takahashi, J | 1 |
| Danhof, M; DeJongh, J; Scott, G; Stringer, F | 1 |
3 trial(s) available for thiazoles and sipoglitazar
| Article | Year |
|---|---|
The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent.
Topics: Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Biotransformation; Cross-Over Studies; Double-Blind Method; Female; Glucuronosyltransferase; Half-Life; Heterozygote; Homozygote; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Middle Aged; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Propionates; Thiazoles; United Kingdom; Young Adult | 2013 |
Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Genotype; Glucuronosyltransferase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Models, Biological; Peroxisome Proliferator-Activated Receptors; Polymorphism, Genetic; Propionates; Thiazoles; Young Adult | 2013 |
A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Genotype; Glucuronosyltransferase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Peroxisome Proliferator-Activated Receptors; Polymorphism, Genetic; Propionates; Rosiglitazone; Thiazoles; Thiazolidinediones | 2014 |
3 other study(ies) available for thiazoles and sipoglitazar
| Article | Year |
|---|---|
An unusual metabolic pathway of sipoglitazar, a novel antidiabetic agent: cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide.
Topics: Alkylation; Animals; Aryl Hydrocarbon Hydroxylases; Biocatalysis; Cells, Cultured; Cytochrome P-450 CYP2C8; Dogs; Enzyme Inhibitors; Glucuronates; Glucuronides; Glucuronosyltransferase; Hepatocytes; Humans; Hypoglycemic Agents; Microsomes, Liver; Molecular Structure; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptors; Propionates; Recombinant Proteins; Substrate Specificity; Thiazoles; Uridine Diphosphate Glucuronic Acid | 2012 |
Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-γ, -α and -δ, in rats and monkeys and comparison with humans in vitro.
Topics: Administration, Oral; Animals; Humans; Macaca fascicularis; Male; Metabolic Clearance Rate; PPAR alpha; PPAR delta; PPAR gamma; Propionates; Rats; Rats, Sprague-Dawley; Species Specificity; Thiazoles; Tissue Distribution | 2012 |
UDP-glucuronosyltransferase 2B15 (UGT2B15) is the major enzyme responsible for sipoglitazar glucuronidation in humans: retrospective identification of the UGT isoform by in vitro analysis and the effect of UGT2B15*2 mutation.
Topics: Genotype; Glucuronosyltransferase; Humans; Kinetics; Oxazepam; Propionates; Retrospective Studies; Thiazoles | 2013 |